Galapagos NV (NASDAQ:GLPG) shares hit a new 52-week high on Wednesday . The company traded as high as $101.44 and last traded at $101.39, with a volume of 87,494 shares traded. The stock had previously closed at $100.56.

A number of research analysts have weighed in on the stock. Stifel Nicolaus upgraded shares of Galapagos NV from a “hold” rating to a “buy” rating and upped their price objective for the stock from $83.00 to $101.00 in a research report on Friday, August 11th. Zacks Investment Research upgraded shares of Galapagos NV from a “hold” rating to a “buy” rating and set a $86.00 price objective for the company in a research report on Friday, July 14th. TheStreet upgraded shares of Galapagos NV from a “d+” rating to a “c” rating in a research report on Wednesday, May 17th. BTIG Research reiterated a “buy” rating and issued a $98.00 price objective on shares of Galapagos NV in a research report on Tuesday, June 20th. Finally, BidaskClub upgraded shares of Galapagos NV from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $101.50.

Several large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC purchased a new stake in Galapagos NV during the first quarter worth about $161,000. Acadian Asset Management LLC purchased a new stake in Galapagos NV during the second quarter worth about $166,000. New York State Common Retirement Fund purchased a new stake in Galapagos NV during the second quarter worth about $166,000. Bank of Montreal Can boosted its holdings in Galapagos NV by 8,736.4% during the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock worth $168,000 after buying an additional 1,922 shares in the last quarter. Finally, Pacad Investment Ltd. purchased a new stake in Galapagos NV during the second quarter worth about $168,000. 23.63% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/09/13/galapagos-nv-glpg-sets-new-12-month-high-at-101-44.html.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.